Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 1/20 | 0.67 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.67 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4794765 | 0.84 | APOBEC3A (0.61) | APOBEC3AAPOBEC3GKDM4EALDH1A1HPGD | |
| SCHEMBL13995847 | 0.82 | APOBEC3A (0.73) | APOBEC3AAPOBEC3GSTING1KDM4EALDH1A1 | |
| SCHEMBL4312244 | 0.81 | APOBEC3A (0.67) | APOBEC3AAPOBEC3GKDM4EALDH1A1HSD17B10 | |
| SCHEMBL569917 | 0.80 | APOBEC3A (1.00) | APOBEC3AAPOBEC3GKDM4EALDH1A1HSD17B10 | |
| SCHEMBL14249152 | 0.79 | APOBEC3A (0.73) | APOBEC3AAPOBEC3GKDM4EALDH1A1HSD17B10 | |
| SCHEMBL23034387 | 0.78 | POLB (0.50) | APOBEC3AAPOBEC3GSTING1KDM4EHPGD | |
| SCHEMBL17883352 | 0.78 | APOBEC3A (0.67) | APOBEC3AAPOBEC3GKDM4EALDH1A1HSD17B10 | |
| SCHEMBL17321385 | 0.78 | APOBEC3A (0.67) | APOBEC3AAPOBEC3GKDM4EALDH1A1HSD17B10 | |
| SCHEMBL17460372 | 0.78 | APOBEC3A (0.61) | APOBEC3AAPOBEC3GKDM4EALDH1A1HSD17B10 | |
| SCHEMBL297434 | 0.76 | MAPK1 (0.47) | APOBEC3AAPOBEC3GKDM4EPOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025087365-A1 | METTL3 INHIBITOR | 杭州邦顺制药有限公司 | 2025-05-01 | — | — | WO | disclosed |
| CN-119899188-A | METTL3 inhibitors | 杭州邦顺制药有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210154178-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10952996-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200188370-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | US | disclosed |
| WO-2020123453-A2 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | WO | disclosed |
| US-10131669-B2 | Pyrazolopyrimidine compounds | PFIZER INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20170204099-A1 | Pyrazolopyrimidine Compounds | PFIZER INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204099-A1 | Pyrazolopyrimidine Compounds | PFIZER INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204099-A1 | Pyrazolopyrimidine Compounds | PFIZER INC. (US) | 2017-07-20 | — | — | US | disclosed |
| EP-3172210-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | Pfizer Inc (US) | 2017-05-31 | — | — | EP | disclosed |
| WO-2016012896-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016012896-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| EP-2054416-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10131669-B2 | Pyrazolopyrimidine compounds | PDE4B, PDE4A, PDE7A | APOBEC3A 2375/4885APOBEC3G 2477/4885STING1 4103/4885 |
| US-10952996-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | APOBEC3A 3563/4885APOBEC3G 3283/4885STING1 2528/4885 |
| US-20210154178-A1 | ALK5 INHIBITORS | ALK, ACVR1, ACVRL1 | APOBEC3A 3563/4885APOBEC3G 3283/4885STING1 2528/4885 |
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | APOBEC3A 3563/4885APOBEC3G 3283/4885STING1 2528/4885 |
| US-20170204099-A1 | Pyrazolopyrimidine Compounds | DPYD, QDPR, ABCG2 | APOBEC3A 3427/4885APOBEC3G 3441/4885STING1 4498/4885 |
| US-20200188370-A1 | ALK5 INHIBITORS | ALK, ACVR1, ACVRL1 | APOBEC3A 3563/4885APOBEC3G 3283/4885STING1 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.